- Home
- UHT vs CRVS Comparison
UHT vs CRVS Comparison
Compare UHT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHT
- CRVS
- Stock Information
- Founded
- UHT 1986
- CRVS 2014
- Country
- UHT United States
- CRVS United States
- Employees
- UHT N/A
- CRVS N/A
- Industry
- UHT Real Estate Investment Trusts
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- UHT Real Estate
- CRVS Health Care
- Exchange
- UHT Nasdaq
- CRVS Nasdaq
- Market Cap
- UHT 515.7M
- CRVS 459.0M
- IPO Year
- UHT N/A
- CRVS 2016
- Fundamental
- Price
- UHT $36.45
- CRVS $7.86
- Analyst Decision
- UHT
- CRVS Strong Buy
- Analyst Count
- UHT 0
- CRVS 4
- Target Price
- UHT N/A
- CRVS $13.75
- AVG Volume (30 Days)
- UHT 74.4K
- CRVS 1.0M
- Earning Date
- UHT 10-24-2025
- CRVS 11-11-2025
- Dividend Yield
- UHT 8.13%
- CRVS N/A
- EPS Growth
- UHT N/A
- CRVS N/A
- EPS
- UHT 1.30
- CRVS N/A
- Revenue
- UHT $99,952,000.00
- CRVS N/A
- Revenue This Year
- UHT N/A
- CRVS N/A
- Revenue Next Year
- UHT $0.81
- CRVS N/A
- P/E Ratio
- UHT $28.05
- CRVS N/A
- Revenue Growth
- UHT 0.31
- CRVS N/A
- 52 Week Low
- UHT $34.56
- CRVS $2.54
- 52 Week High
- UHT $43.38
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- UHT 39.58
- CRVS 63.57
- Support Level
- UHT $36.04
- CRVS $6.81
- Resistance Level
- UHT $37.16
- CRVS $7.98
- Average True Range (ATR)
- UHT 0.75
- CRVS 0.55
- MACD
- UHT 0.10
- CRVS -0.03
- Stochastic Oscillator
- UHT 55.10
- CRVS 92.45
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).